Cereno Scientific Provides Update on Expanded Access Program for CS1 – initial learnings expected in Q1 2026

Cereno Scientific completed the 12-month active study period of its CS1 Expanded Access Program in pulmonary arterial hypertension, enrolling 10 patients who previously finished the Phase IIa trial; initial EAP learnings are expected in Q1 2026 with further analyses in Q2 2026. CS1, an oral HDAC inhibitor with U.S. FDA Fast Track (Aug 2025) and Orphan Drug Designations (U.S. and EU), showed tolerability and promising efficacy signals in Phase IIa, and the company is preparing a global Phase IIb with first patient enrollment targeted in Q2 2026 — a sequence of near-term data and development milestones that could inform valuation ahead of the Phase IIb study.

Analysis

Market structure: A positive Q1 2026 EAP readout and on‑track Phase IIb (first patient H2‑Q2 2026) would most directly benefit Cereno Scientific (Nasdaq First North: CRNO B), niche HDACi developers and specialty CROs doing PAH imaging; incumbents selling symptom‑management PAH drugs (e.g., prostacyclin and ERA providers) face gradual share erosion if CS1 proves disease‑modifying, potentially capturing 10–30% of addressable PAH add‑on market over 3–5 years. Supply/demand is currently supply‑constrained (n=10 EAP) so positive signals will create a rapid demand shock requiring manufacturing scale‑up and likely contract manufacturing agreements within 6–12 months. Cross‑asset: expect outsized idiosyncratic equity volatility and option IV spikes around readouts, modest widening of credit spreads for comparable small biotechs, and FX sensitivity (SEK/USD funding mix) if U.S. trials accelerate.

Key Decisions for Investors

• Establish a 2–3% long position in Cereno Scientific (CRNO B) over the next 4–8 weeks ahead of the Q1 2026 EAP initial learnings; plan to trim 50% of the position on a clearly positive safety + imaging signal, target 40–100% upside within 3–9 months, set a hard stop‑loss at −30% (or hedge with puts).
• If seeking leveraged exposure, buy a 9–12 month call spread (size 1–2% of portfolio notional) on CRNO B with strikes ~25%–75% OTM to limit premium; simultaneously buy 9–12 month puts 30% OTM covering 50% of the long notional to protect against a clinical/regulatory downside (cost‑effective collar).
• Implement a pair trade to reduce sector beta: long CRNO B (2%) vs short IBB (−1%) or UTHR (−0.5%) to capture PAH‑specific upside while hedging broad biotech moves; rebalance if CRNO B outperforms by >60% or if Phase IIb enrollment slips >30 days.
• Avoid sizing >5% total portfolio exposure to CRNO B given high dilution probability; anticipate a capital raise within 12 months—if management announces a financing window, reduce position by at least 40% unless funding is non‑dilutive partnership financing.
• Monitor three binary triggers with concrete actions: (1) EAP initial readout in Q1 2026 — buy/hold on positive safety+imaging, sell/hedge on adverse; (2) Phase IIb first‑patient date in Q2 2026 — accelerated enrollment should be bullish; (3) any FDA/EMA regulatory feedback or clinical hold — immediately reduce exposure by 50%.